• Mashup Score: 2
    Second primary malignancy after treatment with ruxolitinib - 4 year(s) ago

    Francesca Palandri, PhD, MD, University Hospital, Bologna, Italy, explores the incidence of second primary malignancies after treatment with ruxolitinib. This…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: How does ruxolitinib treatment effect second primary malignancies w/ Francesca Palandri of University of Bologna: https://t.co/7wiVmIZBRf @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #Oncoalert #EHAtrending #EHA25Virtual @OncoAlert

  • Mashup Score: 1
    The evolving CLL treatment paradigm - 4 year(s) ago

    Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, highlights novel targeted therapies in development for chronic lymphocytic leukemia…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Video: The evolving #CLL treatment paradigm explained by Carsten Niemann of @uni_copenhagen: https://t.co/G5dCK9fZsm @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #Oncoalert #EHAtrending #EHA25Virtual @OncoAlert #Leusm #Leukemia

  • Mashup Score: 3
    Updates from UK NCRI AML18 - 4 year(s) ago

    Nigel Russell, MD, of Guy’s Hospital NHS Trust, London, UK, discusses results from the UK NCRI AML18 trial (NCT02272478) investigating…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: Updates from trial UK NCRI #AML18 w/ Nigel Russel of @GSTTnhs: https://t.co/rkibB9LQWw @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #Oncoalert #EHAtrending #EHA25Virtual #CTsm @OncoAlert #CTsm #Leusm #Leukemia

  • Mashup Score: 0
    Tisagenlecleucel in pediatric R/R B-cell ALL - 4 year(s) ago

    Andre Baruchel, MD, PhD, of Hôpital Robert Debre, Paris, France, discusses tisagenlecleucel for pediatric/young adult patients with relapsed/refractory (R/R) B-cell…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: #Tisagenlecleucel in pediatric R/R B-cell #ALL w/ Andre Baruchel of @HopRobertDebre: https://t.co/LYKN1S3XR2 @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #Oncoalert #EHAtrending #EHA25Virtual @OncoAlert #Leusm #Leukemia #ImmunoOnc #tcellrx https://t.co/462cyJb36g

  • Mashup Score: 6
    Biomarkers in ultra low-risk myeloma - 4 year(s) ago

    Meral Beksac, MD, Ankara University, Ankara, Turkey, evaluates biomarkers of response in ultra low-risk multiple myeloma and the development of…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: Biomarkers in ultra low-risk #Myeloma w/ @mbeksac56 of @AnkaraUni: https://t.co/gdAwvgptUl @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #Oncoalert #EHAtrending #EHA25Virtual @OncoAlert #MMsm

  • Mashup Score: 0
    Significance of IKZF1 deletions in pediatric ALL - 4 year(s) ago

    Anthony Moorman, PhD, Newcastle University, Newcastle, UK talks on IKZF1 (Ikarus) deletions in pediatric acute lymphoblastic leukemia (ALL) and whether…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: What is the significance of IKZF1 deletions in paediatric #ALL w/ Anthony Moorman of @UniofNewcastle: https://t.co/EqyR62HPfb @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #Oncoalert #EHAtrending #EHA25Virtual @OncoAlert #Leusm #Leukemia

  • Mashup Score: 0
    NGS: changes in CLL management - 4 year(s) ago

    Richard Rosenquist Brandell, MD, of Karolinska Institute, Solna, Stockholm, discusses how the management of chronic lymphocytic leukemia (CLL) has changed…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: How has the treatment of #CLL changed since the emergence of next-generation techniques w/ Richard Rosenquist of @karolinskainst : https://t.co/9Lw5HT2Mr6 @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #Oncoalert #EHAtrending #EHA25Virtual @OncoAlert #Leusm #Leukemia

  • Mashup Score: 0
    Mitigating smoldering myeloma progression risk - 4 year(s) ago

    Sagar Lonial, MD, of Winship Cancer Institute of Emory University, Atlanta, GA, discusses new insights on smoldering myeloma and the…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: Mitigating smoldering #Myeloma progression risk w/ @SagarLonialMD of @EmoryUniversity: https://t.co/7ToG2hz1Wy @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #Oncoalert #EHAtrending #EHA25Virtual @OncoAlert #Myeloma #MMsm #SmolderingMyeloma

  • Mashup Score: 0
    Bispecific antibodies for non-Hodgkin lymphoma - 4 year(s) ago

    Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, reflects on the use of bispecific antibodies in the treatment of…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: Bispecific antibodies for non-Hodgkin #Lymphoma w/ Martin Hutchings of @uni_copenhagen: https://t.co/SFW4pE4nni @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #Oncoalert #EHAtrending #EHA25Virtual @OncoAlert #Lymsm #Lymphoma #ImmunoOnc

Load More